Sensorion Announces the Positive Data Safety Monitoring Board (DSMB) Review and Continuation of the Phase 2 Clinical Trial for SENS-111 in Acute Unilateral Vestibulopathy (AUV)

81

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, today announced that the independent Data Safety Monitoring Board (or DSMB) has undertaken a review of the safety data for the 76 first patients having completed the phase 2 clinical trial for S http://www.businesswire.com/news/home/20190514006141/en/Sensorion-Announces-Positive-Data-Safety-Monitoring-Board/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

- Advertisement -